Advertisements



Onconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing Trial

A look at how the company is trying to use the Ras oncogne to tackle leukemiaRelated Stocks: ONTX,.....»»

Category: worldSource: nytJan 12th, 2018

UPDATE: Onconova Therapeutics stock surges 7% on positive mid-stage clinical trial results

Onconova Therapeutics Inc. stock surged 7% in morning trade Monday after the company said its drug had positive results in a mid-stage clinical trial for patients with higher-risk myelodysplastic syndromes, conditions that are considered a .....»»

Category: topSource: marketwatchJun 5th, 2017

Acorda Therapeutics plummets as much as 13% on failed trial, discontinued drug development

The latest results for a post-stroke walking difficulties drug weren’t clinically meaningful......»»

Category: topSource: marketwatchNov 21st, 2016

Acorda Therapeutics sinks 13% on discontinuation of drug for post-stroke walking

Acorda Therapeutics Inc. shares dropped as much as 13.2% in pre-market trade Monday after the company said it was discontinuing development of its drug intended for post-stroke walking difficulties after a clinical trial failure. Despite promising result.....»»

Category: topSource: marketwatchNov 21st, 2016

Acorda Therapeutics Sinks 13% On Discontinuation Of Drug For Post-stroke Walking

Acorda Therapeutics Inc. shares dropped as much as 13.2% in pre-market trade Monday after the company said it was discontinuing development of its drug intended for post-stroke walking difficulties after a clinical trial failure......»»

Category: topSource: foxnewsNov 21st, 2016

The hottest thing in cancer drug development is a takeover target again — here"s what you need to know about it (JUNO, CELG)

AP Biotech giant Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal goes through, it'd be the second deal in the past few months for companies working on treatments that.....»»

Category: topSource: businessinsiderJan 17th, 2018

Is Cara Therapeutics, Inc. a Buy?

Is a setback in a trial of its only clinical drug a warning to stay away from this little biotech?.....»»

Category: topSource: foxnewsDec 18th, 2017

Here"s Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday

What happened Shares of clinical stage biopharma Marinus Pharmaceuticals NASDAQ MRNS rose over 41 today after larger peer Sage Therapeutics NASDAQ SAGE reported positive top line results for one of its drug candidates SAGE 217 in a phase 2 trial in major.....»»

Category: futuresSource: nasdaqDec 7th, 2017

Could Sage Therapeutics’ Depression Drug Be the Next Big Thing?

Sage Therapeutics saw its shares make an incredible gain on Thursday after the firm announced positive top-line results from its midstage trial......»»

Category: blogSource: 247wallstDec 7th, 2017

Charting the Market: Sage Therapeutics Could Cure Your Blues

In a mid-phase study of an antidepressant under development by Sage Therapeutics, the novel drug worked faster and more effectively than currently-marketed treatments......»»

Category: blogSource: barronsDec 7th, 2017

With latest drug trial, Sage catapults into top 5 most valuable Mass. biotechs

Sage Therapeutics saw its market cap jump more than $2.5 billion on Thursday after announcing that one of its depression drugs had aced a mid-stage trial, vaulting the Cambridge-based company into the state’s top five most valuable biotechs. Sag.....»»

Category: topSource: bizjournalsDec 7th, 2017

Brace for a Coming Wave of Cancer-Drug Trial Failures: Gadfly

Brace for a Coming Wave of Cancer-Drug Trial Failures: Gadfly.....»»

Category: topSource: washpostNov 28th, 2017

Acorda Therapeutics crashes 40% after patients die in drug trial (ACOR)

M.....»»

Category: topSource: businessinsiderNov 15th, 2017

Sage Therapeutics to seek approval of postpartum depression drug after trial win

Cambridge biotech Sage Therapeutics says it plans to apply for U.S. approval of its experimental drug to treat postpartum depression next year after the drug achieved the main goals in two late-stage trials involving more than 200 women. Sage (Na.....»»

Category: topSource: bizjournalsNov 9th, 2017

Global Blood Therapeutics stock declines after forsaking half its drug pipeline

After investing millions in research and development, the company said the drug didn’t work well enough to keep going......»»

Category: topSource: marketwatchOct 23rd, 2017

What"s Behind Celldex Therapeutics, Inc."s 16% Rally in September?

It looks like impatient investors anticipating news from an ongoing pivotal trial drove up the stock last month......»»

Category: topSource: foxnewsOct 6th, 2017

Halozyme Therapeutics Wins Big on Roche License Agreement

Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an........»»

Category: blogSource: 247wallstSep 14th, 2017

Sage Therapeutics Falls Hard After Brexanolone Drug Fails Phase III Testing

Shares of SAGE Therapeutics Inc (NASDAQ: SAGE) plunged Tuesday after the biopharma company announced its treatment for super-refractory status epilepticus failed its phase III trial. Latest Ratin.....»»

Category: blogSource: benzingaSep 12th, 2017

Here"s Why Spark Therapeutics Inc. Surged 23.5% in August

Revealing positive clinical trial data for a bleeding-disorder candidate increased confidence for the company's proprietary gene therapy development platform......»»

Category: topSource: foxnewsSep 6th, 2017

Aratana sniffs out new use for dog drug in cats

Aratana Therapeutics reported positive results from a trial in a local anesthetic for man’s best friend tested in felines. It's the second trial the Leawood-based animal health company had conducted on the treatment, currently marketed for dogs .....»»

Category: topSource: bizjournalsJul 26th, 2017

Inside Sarepta"s Beat And Raise Q2

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped up over 17 percent during Wednesday’s after-hours trading sessions, after the medical research and drug development company crushed earnings estimates. Latest Rating.....»»

Category: blogSource: benzingaJul 20th, 2017